Bio-Matrix (BMSN) and its majority-owned subsidiary, Entest BioMedical have finalized an agreement with Therinject for the development of a new immuno-therapeutic cancer vaccine.
Reportedly, it is anticipated that BMSN’s facilities and infrastructure will be utilized by both the parties for the development of immuno-therapeutic treatments for cancer.
Initially, BMSN and Therinject planned to focus on the veterinary market, looking to treat animals with tumors while gathering data in support of human clinical trials.
Additionally, Therinject will work with Entest BioMedical’s team to develop intellectual property in this area of cancer treatment, which is anticipated to result in patents being applied for, by Entest BioMedical.
David Koos, chairman and CEO of Bio-Matrix said: “Cancer is the 1 cause of death among dogs. It’s estimated that 1 out of every 3 dogs will get cancer. We anticipate this immuno-therapeutic cancer vaccine could have an efficacy rate of as high as 60% where 15% to 20% is the current cure rate. We believe that during the first year this immuno-therapeutic vaccine is available we will treat roughly 2,000 animals resulting in $3,000 revenue per animal or $6 million in first year revenue from veterinary medical applications. The company anticipates a market niche over the subsequent 5 years of 40,000 animals being treated. This is before we expand to human clinical trials.”